伊立替康联合洛铂治疗复发性广泛期小细胞肺癌（SCLC）的临床研究

目的：观察伊立替康联合洛铂方案治疗复发性小细胞肺癌（ SCLC）的疗效和毒副反应。方法：选取36例SCLC患者，予伊立替康200mg/m2加入生理盐水250ml中，稀释后静滴1.5h，第1天；洛泊35mg/m2加入5％葡萄糖500ml中，稀释后静滴2h，第1天，每21d为1个周期，2个周期后评价疗效和毒副反应。结果：36例均可评价疗效，完全缓解（ CR）1例，部分缓解（ PR）13例，疾病稳定（ SD）11例，疾病进展（ PD）11例，客观缓解率（ ORR）为38.9％，疾病控制率（ DCR）为69.4％，中位无进展生存期（ PFS）为4.6个月，中位生存期（OS）为7.8个月。毒副反应主要为血液学毒性和消化道毒性，3/4级白细胞减少、血红蛋白减少和血小板减少发生率分别为41.7％（15/36）、50.0％（18/36）、72.2％（26/36）；腹泻发生率为69.4％（25/36），其中3、4级腹泻为13.9％（5/36）。全组无毒性相关死亡。结论：伊立替康联合洛铂方案用于治疗复发性SCLC有较好的疗效，毒副反应可耐受。

Clinical observation of combined chemotherapy of lobaplatin and irinotecan in the treat-ment of extensive relapsed small-cell lung cancer

Objective：To observe the efficacy and safety of chemotherapy consisted of lobaplatin and irinotecan for patients with relapsed（ extensive small -cell lung cancer,ED -SCLC ）. Methods：The first day,36 patients with SCLC were treated with 1. 5h intravenous infusion of CTP 200mg/m2 diluted in 250ml saline,lobaplatin 35mg/m2 di-luted in 500ml 5% glucose,with intravenous infusion for 2h,21 days as a cycle. Results：Thirty-six patients were evaluable for response,in which 1 achieved complete response and 13 partial responses,objective responses rate was 38. 9%,11 patients had stable disease and 11 progressive diseases. The disease control rate was 69. 4%. The median time for progression and overall survival was 4. 6 months and 7. 8 months,respectively. The main toxicity was the he-matologic toxicity and gastrointestinal tract side reaction,Grade 3,4 leucopenia was 41. 7%（15/36）,and neutropenia was 50. 0%（18/36）,and thrombocytopenia was 72. 2%（26/36）. Diarrhea was 69. 4%（25/36）,13. 9%（5/36） were grade 3,4. There was no treatment-related death. Conclusion：The combination of lobaplatin and irinotecan is highly active and tolerable in patients with chemotherapy mediate extensive relapsed small-cell lung cancer when it is administered as rescue treatment.